Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
- Saint Luke's Cancer Institute - Boise — Boise, Idaho
- Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
- Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
- Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
- Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho